Arcutis Biotherapeutics Inc expected to post earnings of 4 cents a share - Earnings Preview

Arcutis Biotherapeutics

04/08/2026 01:30

Arcutis Biotherapeutics Inc ARQT.OQ ARQT.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Westlake Village California-based  company is expected to report a 45.8% increase in revenue to $118.852 million from $81.5 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Arcutis Biotherapeutics Inc is for earnings of 4 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $35.00, about 34.9% above its last closing price of $25.94
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.09
-0.08
-0.09
Missed
-9.6
Dec. 31 2026
0.12
0.11
0.13
Beat
14.6
Sep. 30 2025
-0.10
-0.10
0.06
Beat
160.1​
Jun. 30 2025
-0.15
-0.16
-0.13
Beat
17.8
​​Mar. 31 2025
-0.20
-0.21
-0.20
Beat
4.8
Dec. 31 2024
-0.24
-0.25
-0.09
Beat
64.7​
Sep. 30 2024
-0.41
-0.42
-0.33
Beat
20.9
Jun. 30 2024
-0.51
-0.52
-0.42
Beat
18.7
This summary was machine generated August 4 at 00:30 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)